CLINOLIPID 20% (olive oil and soybean oil) by Baxter is production. Approved for including term, preterm neonates, a source of calories and 4 more indications. First approved in 2013.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
CLINOLIPID 20% is a lipid emulsion combining olive oil and soybean oil administered intravenously as a source of calories and essential fatty acids for parenteral nutrition. It is indicated for term and preterm neonates when enteral nutrition is not possible or is insufficient. The drug works through beta-oxidation of fatty acids to produce energy, while also supporting membrane structure, bioactive molecule synthesis, and gene expression regulation.
Product approaching loss of exclusivity in April 2027 with less than one year remaining; brand team likely in defensive/transition mode with minimal expansion headcount.
production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are important for membrane structure and function, precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.
Lipid Emulsion
Worked on CLINOLIPID 20% at Baxter? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
CLINOLIPID offers limited career growth opportunities given its approaching LOE and zero linked job openings. Positions on this product are primarily defensive, focusing on market maintenance and generic transition management rather than innovation or expansion.